Opinion|Videos|November 15, 2024
Importance of Early Referral for CAR T-cell Therapy in Multiple Myeloma and Patient Quality of Life
Panelists discuss how early referral for chimeric antigen receptor T-cell therapy is crucial for patients, as it helps to overcome potential barriers and ensures timely access to this transformative treatment option.
Advertisement
Episodes in this series
Dr Ajai Chari to Dr Martin: As we know, thereare potential barriers or challenges in referring patients to chimeric antigen receptor (CAR) T-cell therapy; why is it important for patients to be referred early for CAR T-cell therapy?
Advertisement
Related to this article
Estelamari Rodriguez, MD, MPH, discusses the rationale, design, and practice implications of the phase 3 RELATIVITY-1093 trial in nonsquamous NSCLC.
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
The third BLA submission for tabelecleucel follows 2 CRLs and includes updated ALLELE data with additional patients and longer follow-up.
A New England Journal of Medicine report describes complete hepatoblastoma regression in a 3-year-old treated with a novel immunotherapy.
Plinabulin plus docetaxel received fast track designation for pretreated nonsquamous NSCLC without actionable genomic alterations.
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
Denosumab-adet (Degevma) is FDA approved as an Xgeva biosimilar for SRE prevention in myeloma and bone metastases, giant cell tumor of bone, and HCM.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss individualized treatment and strategic sequencing in HER2-mutated NSCLC.
Researchers at Wake Forest University School of Medicine identified a protein that may help breast cancer spread to the brain and evade immune defenses.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
2
CNS Control and Daily Tolerability Guide Treatment Sequencing in HER2-Mutated NSCLC
3
Tabelecleucel BLA Is Resubmitted to FDA for EBV+ Post-Transplant Lymphoproliferative Disease
4
Breast Cancer Experts Highlight Abstracts to Watch at ESMO 2026
5